Abstract | BACKGROUND/AIM: MATERIALS AND METHODS: The experimental metastasis assay was performed by injecting F3II mammary carcinoma cells into the lateral tail vein of syngeneic female BALB/c mice. RESULTS: Clinically relevant doses of dDAVP (0.3 to 2 μg/kg intravenously (i.v.)) produced a dose-dependent inhibition in the formation of lung nodules when administered during the first 24 hours after F3II tumor cell injection. The hemostatic agent tranexamic acid (10 mg/kg, i.v.) had no effect on metastasis formation in the same experimental conditions, while the anticoagulant enoxaparin (1 mg/kg, subcutaneously (s.c.)) did not modify the antimetastatic action of dDAVP. In vitro, dDAVP had a strong inhibitory effect on F3II cell colony formation. CONCLUSION:
dDAVP interferes with early metastatic disease, and direct association of this effect with hemostatic mechanisms is unlikely.
|
Authors | Juan Garona, Marina Pifano, Alejandra M Scursoni, Daniel E Gomez, Daniel F Alonso, Giselle V Ripoll |
Journal | Anticancer research
(Anticancer Res)
Vol. 34
Issue 9
Pg. 4761-5
(Sep 2014)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 25202055
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Deamino Arginine Vasopressin
|
Topics |
- Animals
- Breast Neoplasms
(pathology)
- Cell Line, Tumor
- Deamino Arginine Vasopressin
(administration & dosage, pharmacology)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Female
- Lung Neoplasms
(drug therapy, pathology, secondary)
- Mice
- Mice, Inbred BALB C
- Tumor Burden
(drug effects)
|